SCHEMBL945488

SCHEMBL945488

O=c1[nH]cccc1OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.50
NSD2 O96028 1/20 0.50
ABL1 P00519 1/20 0.50
PPARG P37231 1/20 0.50
RIN1 Q13671 1/20 0.50
NCOR2 Q9Y618 1/20 0.50
MAPT P10636 1/20 0.50
MAPK1 P28482 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
POLB P06746 2/20 0.47
ALPG P10696 1/20 0.47
PTK2B Q14289 1/20 0.47
HTR1A P08908 1/20 0.47
DRD2 P14416 1/20 0.47
LMNA P02545 1/20 0.47
KMT2A Q03164 3/20 0.46
KDM4E B2RXH2 2/20 0.46
BLM P54132 2/20 0.46
GAA P10253 1/20 0.46
CCNB2 O95067 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27922547 0.88 HTT (0.49) L3MBTL1MAPTPOLBALPGPTK2B
SCHEMBL2314773 0.86 KDM4E (0.49) L3MBTL1MAPTPOLBHTR1ALMNA
SCHEMBL3371602 0.82 PARP1 (0.63) L3MBTL1NSD2ABL1PPARGRIN1
SCHEMBL29076818 0.82 LMNA (0.46) LMNAKDM4EMAOBALDH1A1HTT
SCHEMBL4484727 0.78 L3MBTL1 (0.59) L3MBTL1NSD2ABL1PPARGRIN1
SCHEMBL4380048 0.78 MAPK14 (0.51) L3MBTL1NSD2ABL1PPARGRIN1
SCHEMBL5256531 0.77 L3MBTL1 (0.49) L3MBTL1NSD2ABL1PPARGRIN1
SCHEMBL11251911 0.76 IDO1 (0.61) L3MBTL1MAPTMAPK1TDP1HTR1A
SCHEMBL339812 0.76 MAPT (0.71) L3MBTL1MAPTMAPK1TDP1ALPG
SCHEMBL23258867 0.75 MAPT (0.59) L3MBTL1MAPTMAPK1TDP1ALPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025067126-A1 PYRIDONE COMPOUNDS AND PREPARATION METHOD THEREFOR, AND APPLICATION 深圳信立泰药业股份有限公司 2025-04-03 WO disclosed
CN-116768792-B Cinnamamide-hydroxypyridone derivative, and preparation method and application thereof 浙江工业大学 2024-10-18 CN disclosed
CN-116768792-A Cinnamamide-hydroxypyridone derivative, and preparation method and application thereof 浙江工业大学 2023-09-19 CN disclosed
US-9156772-B2 Fluoride-releasing compositions NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-13 US disclosed
US-9156772-B2 Fluoride-releasing compositions NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-13 US disclosed
US-9156772-B2 Fluoride-releasing compositions NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-13 US disclosed
CN-103130714-B Fullerene radical malonamide benzyloxy-pyridone derivative and preparation method thereof UNIV SW SCI & TECH SWUST 2015-06-17 CN disclosed
US-8871728-B2 Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof GEORGIA TECH RESEARCH CORPORATION (US) 2014-10-28 US disclosed
US-20140088308-A1 Fluoride-Releasing Compositions BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2014-03-27 US disclosed
US-20140088308-A1 Fluoride-Releasing Compositions BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2014-03-27 US disclosed
US-6046219-A ADMINISTERING TO THE PATIENT FOR TREATING THE CONDITIONS MEDIATED BY COLLAGEN FORMATION TOGETHER WITH CELL PROLIFERATION A HYDROXYPYRIDINE DERIVATIVE CORNELL RESEARCH FOUNDATION, INC. (US) 2000-04-04 US disclosed
US-5965585-A SUPPRESSING FORMATION OF COLLAGEN AND COLLAGEN-LIKE SUBSTANCES OR BIOSYNTHESIS OF PROCOLLAGEN IN LIVING SYSTEMS BY ADMINISTERING A HYDROXYPYRIDONE COMPOUND ENZYME INHIBITOR OF PROTEIN HYDROXYLASE; ANTISCARRING AGENTS CORNELL RESEARCH FOUNDATION, INC. (US) 1999-10-12 US disclosed
US-5965586-A Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation CORNELL RESEARCH FOUNDATION, INC. (US) 1999-10-12 US disclosed
WO-1999030562-A1 METHOD FOR TREATING FIBROPROLIFERATIVE DISORDERS BY INHIBITORS OF PROTEIN HYDROXYLATION CORNELL RESEARCH FOUNDATION, INC. (US) 1999-06-24 WO disclosed
US-5849587-A Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells CORNELL RESEARCH FOUNDATION, INC. (US) 1998-12-15 US disclosed
US-5789426-A SUPPRESSION FORMATION OF COLLAGEN CORNELL RESEARCH FOUNDATION, INC. (US) 1998-08-04 US disclosed
EP-0831876-A1 METHOD OF INHIBITING VIRAL REPLICATION IN EUKARYOTIC CELLS AND OF INDUCING APOPTOSIS OF VIRALLY-INFECTED CELLS CORNELL RESEARCH FOUNDATION, INC. (US) 1998-04-01 EP disclosed
EP-0808103-A1 PROTEIN HYDROXYLATION INHIBITORS FOR FIBROPROLIFERATIVE DISORDERS CORNELL RESEARCH FOUNDATION, INC. (US) 1997-11-26 EP disclosed
WO-1996041639-A1 METHOD OF INHIBITING VIRAL REPLICATION IN EUKARYOTIC CELLS AND OF INDUCING APOPTOSIS OF VIRALLY-INFECTED CELLS CORNELL RESEARCH FOUNDATION, INC. (US) 1996-12-27 WO disclosed
WO-1996022021-A1 PROTEIN HYDROXYLATION INHIBITORS FOR FIBROPROLIFERATIVE DISORDERS CORNELL RESEARCH FOUNDATION, INC. (US) 1996-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140088308-A1 Fluoride-Releasing Compositions CHERP, ORAI1, CAD L3MBTL1 3592/4885NSD2 4523/4885ABL1 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.